Sanofi Says U.S. Waiting Period for Bioverativ Has Expired
23 Febrero 2018 - 5:44AM
Noticias Dow Jones
By Sonia Amaral Rohter
Sanofi SA (SAN.FR) said on Friday that a U.S. waiting period for
its proposed acquisition of Bioverativ Inc. (BIVV) has expired
without objections.
With the expiration, "the condition to the offer relating to
antitrust approvals has been satisfied," Sanofi said.
The waiting period--a notification program under the U.S.
Hart-Scott-Rodino Antitrust Improvements Act--requires parties to
certain transactions to submit notification to the U.S. Federal
Trade Commission and Department of Justice and wait before the
transaction can be completed.
In January, Sanofi agreed to buy hemophilia drug maker
Bioverativ for approximately $11.6 billion. On Feb. 7, Sanofi
commenced the tender offer, which is scheduled to expire on March
7.
The closing of the offer is still subject to various conditions,
Sanofi said.
Write to Sonia Amaral Rohter at
sonia.amaralrohter@dowjones.com
(END) Dow Jones Newswires
February 23, 2018 06:29 ET (11:29 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Sanofi (EU:SAN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024